Drug Interactions Newsletter

Volume 1, Issue 28, 07/28/2009

Question

Are there any studies evaluating the use of histamine-2 receptor antagonists (H2RA) with clopidogrel (Plavix®) as it relates to clopidogrel's ability to prevent stent thrombosis or platelet aggregation?

Answer

This is part 2 of a 2 part series related to the drug interaction between histamine-2 receptor antagonists (H2RA; cimetidine (Tagamet®), famotidine (Pepcid®; Fluxid ODT®), nizatidine (Axid®), and ranitidine (Zantac®)) and clopidogrel (Plavix®).  Part 1 addressed primarily the pharmacokinetic and pharmacodynamic data regarding the H2RAs and their ability to interact with clopidogrel via the cytochrome P-450 (CYP) enzymes.(1)  This issue will address the presence of any known data with the coadministration of clopidogrel along with H2RAs as it relates to cardiovascular disease (CVD). 

The only data to date that has specifically attempted to evaluate the impact of H2RA use with clopidogrel on CV-related outcomes was a...

......To read the full answer please LOGIN or SUBSCRIBE NOW.